Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors

Abstract

CHD patients without CRFs show a favorable biomarker profile in terms of inflammation and mineral metabolism. Further studies are needed to investigate whether this difference translates into a better prognosis.

Circulating fibroblast growth factor‐23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease

“…Similarly, in population-based cohorts, a positive relationship between FGF-23 and risk of heart failure was found that was independent of renal status [30]. Furthermore, in patients with stable CAD, those who do not present cardiovascular risk factors show lower FGF-23 and higher calcidiol plasma levels than those with risk factors [31].…”

Novel heart failure biomarkers: why do we fail to exploit their potential?

“…In HF, both myocardial and systemic changes in glucose oxidation, catabolism, b-oxidation, and the urea cycle are responsible for observed alterations in metabolite levels [177]. Several studies have shown that a collection of metabolites can serve as diagnostic tools for HF [178][179][180][181]. However, changes in metabolite profiles seem not to be disease specific, because similar differences were observed in serum samples of patients with diseases such as nonHodgkin lymphoma, congestive HF, and communityacquired pneumonia (CAP) [182].…”

AFC1 Compound Attenuated MI/R-Induced Ventricular Remodeling via Inhibiting PDGFR and STAT Pathway

“…Previous studies have demonstrated the importance of growth factors in IHD (Liu et al, 2014; Pello et al, 2015). High level of platelet derived growth factor (PDGF) in infarcted hearts contributed to myocardial inflammation and fibrosis in rats (Zhao et al, 2011).…”